Core Viewpoint - IQVIA Holdings has narrowed its annual profit forecast, reducing the upper end of its outlook due to expected ongoing cancellations of research contracts from pharmaceutical clients [1] Company Summary - The company anticipates that the trend of contract cancellations will continue into the future, impacting its financial performance [1] Industry Summary - The pharmaceutical industry is facing challenges that are leading to a reduction in research contracts, which may affect companies like IQVIA Holdings that rely on these contracts for revenue [1]

Core Insights - The company has successfully launched over ten AI-driven real-world research (AI-RWS) projects targeting prevalent mental health disorders among Chinese youth and elderly patients, marking a significant step in its strategic positioning within the "AI + clinical research" sector in Hong Kong [1] Academic and Research System - The forum gathered 40 leading experts in pediatric, adolescent psychiatry, and elderly cognitive disorders, establishing a comprehensive research system that integrates AI-driven classification, personalized treatment optimization, dynamic efficacy and safety predictions, and early relapse risk warnings [2] Key Sector Layout and Focus Products - **Youth Mental Health Sector**: The company initiated an AI-RWS study covering over 10,000 patients across 30 institutions in 15 cities, focusing on a population of over 30 million affected individuals. The study involves the exploration of combined treatments using its new drug group, which includes various formulations [3] - **Elderly Dementia and BPSD Sector**: The "Star Plan" aims to create the largest real-world database for BPSD in China, targeting 100,000 patients over five years, focusing on non-drug interventions and combination therapies to provide critical data for innovative drug registration and post-market safety evaluations [3] - The core clinical research products include the unique formulation of "Xienka Microtablet" which is recommended for treating mild to moderate dementia and is designed to address swallowing difficulties while showing superior efficacy compared to similar products [4] Commercialization Path and Future Outlook - The company employs a diversified funding model involving collaboration with research hospitals, pharmaceutical companies, government projects, and insurance co-payments, with project values ranging from millions to billions [5] - Future strategies include focusing on AI-RWS research and the development of intelligent physician assistants, aiming to become a global leader in the field while accelerating the transition to AI-driven clinical research services [5]